Prognostic factors in uterine carcinosarcoma: A clinicopathologic study of 25 patients

Cancer

Volumn 82, Issue 3, 1998, Pages 512-519

  Iwasa, Yoko ^a   Haga, Hironori ^a,b   Konishi, Ikuo ^a   Kobashi, Yoichiro ^b   Higuchi, Kayoko ^a,c   Katsuyama, Eiji ^a,d   Minamiguchi, Sachiko ^a   Yamabe, Hirohiko ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b TENRI HOSPITAL   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

^d KYOTO CITY HOSPITAL   (Japan)

Author keywords

Carcinosarcoma; Immunohistochemistry; Malignant mixed mullerian tumor; Prognostic indicators; Uterus

Indexed keywords

CYCLINE; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER SURVIVAL; CARCINOSARCOMA; CASE REPORT; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MIXED MULLERIAN TUMOR; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; UTERUS CARCINOMA; UTERUS SARCOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOSARCOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; MIXED TUMOR, MULLERIAN; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTO-ONCOGENE PROTEINS C-BCL-2; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53; UTERINE NEOPLASMS;

EID: 0032006242     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980201)82:3<512::AID-CNCR13>3.0.CO;2-4     Document Type: Article

References (43)

1. Chuang JT, Van Velden JJ, Graham JB. Carcinosarcoma and mixed mesodermal tumor of the uterine corpus: review of 49 cases. Obstet Gynecol 1970;35:769-80.
2. Barwick KW, LiVolsi VA. Malignant mixed mullerian tumors of the uterus: a clinicopathologic assessment of 34 cases. Am J Surg Pathol 1979;3:125-35.
3. Peters WA III, Kumar NB, Fleming WP, Morley GW. Prognostic features of sarcomas and mixed tumors of the endometrium. Obstet Gynecol 1984;63:550-6.
4. Macasaet MA, Waxman M, Fruchter RG, Boyce J, Hong P, Nicastri AD, et al. Prognostic factors in malignant mesodermal (mullerian) mixed tumors of the uterus. Gynecol Oncol 1985;20:32-42.
5. Colombi RP. Sarcomatoid carcinomas of the female genital tract (malignant mixed mullerian tumors). Semin Diagn Pathol 1993;10:169-75.
6. Spanos WJ, Wharton JT, Gomez L, Fletcher GH, Oswald MJ. Malignant mixed mullerian tumors of the uterus. Cancer 1984;53:311-6.
7. Silverberg SG, Major FJ, Blessing JA, Fetter B, Askin FB, Liao SY, et al. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus: a gynecologic oncology group pathologic study of 203 cases. Int J Gynecol Pathol 1990;9:1-19.
8. Iqbal JB, Ironside JW. Brief report: cerebral metastasis from a malignant mixed mullerian tumour of the uterus. Histopathology 1993;23:277-9.
9. Norris HJ, Roth E, Taylor HB. Mesenchymal tumors of the uterus: II. A clinical and pathologic study of 31 mixed mesodermal tumors. Obstet Gynecol 1966;28:57-63.
10. Schaepman-Van Geuns EJ. Mixed tumors and carcinosarcomas of the uterus evaluated five years after treatment. Cancer 1970;25:72-7.
11. Costa MJ, Khan R, Judd R. Carcinosarcoma (malignant mixed mullerian [mesodermal] tumor) of the uterus and ovary: correlation of clinical, pathologic, and immunohistochemical features in 29 cases. Arch Pathol Lab Med 1991;115:583-90.
12. George E, Manivel JC, Dehner LP, Wick MR. Malignant mixed mullerian tumors: an immunohistochemical study of 47 cases, with histogenetic considerations and clinical correlation. Hum Pathol 1991;22:215-23.
13. Bitterman P, Chun B, Kurman RJ. The significance of epithelial differentiation in mixed mesodermal tumors of the uterus: a clinicopathologic and immunohistochemical study. Am J Surg Pathol 1990;14:317-28.
14. Sreenan JJ, Hart WR. Carcinosarcomas of the female genital tract: a pathologic study of 29 metastatic tumors: further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis. Am J Surg Pathol 1995;19:666-74.
15. De Brito PA, Silverberg SG, Orenstein JM. Carcinosarcoma (malignant mixed mullerian [mesodermal] tumor) of the female genital tract: immunohistochemical and ultrastructural analysis of 28 cases. Hum Pathol 1993;24:132-42.
16. Wynford-Thomas D. Oncogenes and anti-oncogenes: the molecular basis of tumour behaviour. J Pathol 1991; 165:187-201.
17. Berchuck A, Kohler MF, Boente MP, Rodriguez GC, Whitaker RS, Bast RC. Growth regulation and transformation of ovarian epithelium. Cancer 1993;71:545-51.
18. Costa MJ, Vogelsang J, Young LJT. p53 gene mutation in female genital tract carcinosarcomas (malignant mixed mullerian tumors): a clinicopathologic study of 74 cases. Mod Pathol 1994;7:619-27.
19. Mayall F, Rutty K, Campbell F, Goddard H. p53 immunostaining suggests that uterine carcinosarcomas are monoclonal. Histopathology 1994;24:211-4.
20. Costa MJ, Walls J. Epidermal growth factor receptor and c-erbB-2 oncoprotein expression in female genital tract carcinosarcomas (malignant mixed mullerian tumors): clinicopathologic study of 82 cases. Cancer 1996;77:533-42.
21. FIGO. Annual report on the results of treatment of gynecological cancer. Int J Gynecol Obstet 1989;28:189-93.
22. Scully RE, Bonfiglio TA, Kurman RJ, Silverberg SG, Wilkinson EJ. Histological typing of female genital tract tumours. In: World Health Organization. International histologic classification of tumours. 2nd ed. Berlin: Springer-Verlag, 1994:14-18.
23. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma. A highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982;6:93-108.
24. Abeler VM, Kjorstad KE, Berle E. Carcinoma of the endometrium in Norway: a histopathological and prognostic survey of a total population. Int J Gynecol Cancer 1992;2:9-22.
25. Hsu S-M, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-80.
26. Kalbfleisch JD, Prentice RL. Marginal likelihoods based on Cox's regression and life model. Biometrics 1973;35:25-39.
27. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972;34:187-202.
28. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
29. Schweizer W, Demopoulos R, Beller U, Dubin N. Prognostic factors for malignant mixed mullerian tumors of the uterus. Int J Gynecol Pathol 1990;9:129-36.
30. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318-27.
31. Purdie CA, O'Grady J, Piris J, Wyllie AH, Bird CC. p53 expression in colorectal tumors. Am J Pathol 1991;138:807-13.
32. Barnes DM, Dublin EA, Fischer J, Levison DA, Millis RR. Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum Pathol 1993;24:469-76.
33. Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 1995;26:1268-74.
34. Wynford-Thomas D. p53 in tumour pathology: can we trust immunocytochemistry? J Pathol 1992;166:329-30.
35. Soong R, Robbins PD, Dix BR, Grieu F, Lim B, Knowles S, et al. Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Hum Pathol 1996;27:1050-5.
36. LeBrun DP, Kamel OW, Cleary ML, Dorfman KF, Warnke RA. Follicular lymphomas of the gastrointestinal tract: pathologic features in 31 cases and bcl-2 oncogenic protein expression. Am J Pathol 1992;140:1327-35.
37. Salomon RN, Diaz-Cano S. Minireview in molecular pathology: introduction to apoptosis. Diagn Mol Pathol 1995; 4:235-8.
38. Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, Gerlach C, et al. Immunohistochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 1991;138:867-73.
39. Hall PA, Levison DA, Woods AL, Yu CC-W, Kellock DB, Watkins JA, et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 1990;162:285-94.
40. Dallenbach-Hellweg G. Histopathology of endometrium. 3rd ed. Berlin: Springer-Verlag, 1981:204-10.
41. Emoto M, Iwasaki H, Kikuchi M, Ishiguro M, Kubota T, Izumi H, et al. Two cell lines established from mixed mullerian tumors of the uterus: morphologic, immunocytochemical, and cytogenetic analysis. Cancer 1992;69:1759-68.
42. Emoto M, Iwasaki H, Kikuchi M, Shirakawa K. Characteristics of cloned cells of mixed mullerian tumor of the human uterus: carcinoma cells showing myogenic differentiation in vitro. Cancer 1993;71:3065-75.
43. Gorai I, Doi C, Minaguchi H. Establishment and characterization of carcinosarcoma cell line of the human uterus. Cancer 1993;71:775-86.